Mixed Treatment Comparisons, Network Meta-Analysis (NMA)

Bayesian statistics, convergence diagnostics

Read More

 

Health Economics Modeling: Cost-Effectiveness, Budget Impact

Markov and semi-Markov models, microsimulation, DICE

Read More

 

Real World Studies (cohorts, databases, SNDS)

Econometrics, flexible and predictive models (spline), bayesian methods, CE-CU model inputs, population, external validation, calibration

Read More

 

Open Data, data science, social networks

Statistical reports, machine learning, modeling, care pathway, process mining (organisational impact)

Read More

 

Health economics and Statistics

 

 

 

Welcome!

Statésia is a research and consulting firm specialized in comparative effectiveness research and medico-economic analysis of health technologies and strategies (for hospitals, drug and medical device manusfacturers, consultancy firms, health institutions, HAS DEAI, CT, CEESP, CEPS).

This decision analysis is based on:

1- Comparative Effectiveness Research, Indirect and Mixed Treatment Comparisons (MTC, NMA) : Positioning your innovative technology in the studied therapeutic area;

2- Interactive Health Economics Modeling: Assessing the cost-effectiveness, the cost-utility or the cost-benefit of your innovative health product or technology;

3- Interactive Budget Impact Analysis (IBIA) : Assessing the affordability of your innovative product;

4- Medico-economic real life studies.

 

 

 

 

FaLang translation system by Faboba

News

News: Celebrating an Educational Milestone Franck MAUNOURY (PhD, HDR), CEO STATESIA, associate professor, and MSc Health Economics co-founder/co-chair at Le Mans Université (GAINS, IRA), defended a professorial university thesis (HDR), obtained on 29 november 2023 at Le Mans Université (institutional weblink).

PublicationMaunoury F1,2, Drugeon B3, Boisson M4,5, Marjanovic N3, Couvreur R3,4, Mimoz O3,4,6, Guenezan J3,4,6, on behalf of the CLEAN-3 Study. Cost-effectiveness analysis of bundled innovative devices versus standard approach in the prevention of unscheduled peripheral venous catheters removal due to complications in France. PLoS One. 2022.

1 Statesia, Le Mans, France; 2 University of Le Mans, GAINS, IRA, Le Mans, France; 3 University Hospital of Poitiers, Emergency Department and Pre-Hospital Care, France; 4 University of Poitiers, School of Medicine and Pharmacy, Poitiers, France; 5 University Hospital of Poitiers, Anesthesia, Intensive Care and Peri-Operative Medicine Department, France; 6 INSERM U1070, Pharmacology of anti-infective drugs, Poitiers, France.

PublicationMaunoury F1, Oury A2, Fortin S2, Thomassin L3, Bohbot S3; Explorer Study. Cost-effectiveness of TLC-NOSF dressings versus neutral dressings for the treatment of diabetic foot ulcers in France. PLoS One. 2021 Jan 22;16(1):e0245652. doi: 10.1371/journal.pone.0245652. PMID: 33481840; PMCID: PMC7822547.

1 Health Economics, Statesia, Le Mans, France. 2 Global Regulatory Affairs & Market Access, URGO Medical, Chenôve, France. 3 Global Medical Affairs, URGO Medical, Paris, France.

PublicationSalah Ghabri PhD1, Aymeric Binard MD2, Yves-Marie Pers MD3, Franck Maunoury PhD4, J. Jaime Caro MD,CM, FRCPC, FACP567. Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France. Value in Health DOI: https://doi.org/10.1016/j.jval.2019.12.003. Available online 13 February 2020.

1 Department of Economic and Public Health Evaluation, French National Authority for Health (HAS), Saint-Denis La Plaine, France 2 Department of Rheumatology, CHU de la Cavale-Blanche, Brest, France 3 Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital, Montpellier, France 4 STATESIA, Le Mans, France 5 McGill University, Montreal, QC, Canada 6 London School of Economics, London, England, UK 7 Evidera, Boston, MA, USA .

top arrow